260 related articles for article (PubMed ID: 26049755)
1. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
2. Targeting the programmed death-1 pathway in lymphoid neoplasms.
Ok CY; Young KH
Cancer Treat Rev; 2017 Mar; 54():99-109. PubMed ID: 28242522
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of immune checkpoint inhibition in malignant lymphoma.
Hude I; Sasse S; Engert A; Bröckelmann PJ
Haematologica; 2017 Jan; 102(1):30-42. PubMed ID: 27884973
[TBL] [Abstract][Full Text] [Related]
4. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
Fessas P; Lee H; Ikemizu S; Janowitz T
Semin Oncol; 2017 Apr; 44(2):136-140. PubMed ID: 28923212
[TBL] [Abstract][Full Text] [Related]
5. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
6. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
7. Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma.
Oncale MB; Maymani H; Nastoupil LJ
Blood Lymphat Cancer; 2017; 7():1-7. PubMed ID: 31360081
[TBL] [Abstract][Full Text] [Related]
8. Advances in targeted therapy for malignant lymphoma.
Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
[TBL] [Abstract][Full Text] [Related]
9. Ageing microenvironment mediates lymphocyte carcinogenesis and lymphoma drug resistance: From mechanisms to clinical therapy (Review).
Zhang Y; Chu J; Hou Q; Qian S; Wang Z; Yang Q; Song W; Dong L; Shi Z; Gao Y; Meng M; Zhang M; Zhang X; Chen Q
Int J Oncol; 2024 Jun; 64(6):. PubMed ID: 38757347
[TBL] [Abstract][Full Text] [Related]
10. Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy.
Grover NS; Park SI
Pharmaceuticals (Basel); 2015 Sep; 8(3):607-36. PubMed ID: 26393619
[TBL] [Abstract][Full Text] [Related]
11. Research progress on the mechanism of common inflammatory pathways in the pathogenesis and development of lymphoma.
Shi A; Yun F; Shi L; Liu X; Jia Y
Ann Med; 2024 Dec; 56(1):2329130. PubMed ID: 38489405
[TBL] [Abstract][Full Text] [Related]
12. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
13. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Xia Y; Jeffrey Medeiros L; Young KH
Biochim Biophys Acta; 2016 Jan; 1865(1):58-71. PubMed ID: 26432723
[TBL] [Abstract][Full Text] [Related]
14. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.
Carbognin L; Pilotto S; Milella M; Vaccaro V; Brunelli M; Caliò A; Cuppone F; Sperduti I; Giannarelli D; Chilosi M; Bronte V; Scarpa A; Bria E; Tortora G
PLoS One; 2015; 10(6):e0130142. PubMed ID: 26086854
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
16. Evolving Concepts: Immunity in Oncology from Targets to Treatments.
Khan H; Gucalp R; Shapira I
J Oncol; 2015; 2015():847383. PubMed ID: 26060497
[TBL] [Abstract][Full Text] [Related]
17. Update on checkpoint blockade therapy for lymphoma.
Kline J; Bishop MR
J Immunother Cancer; 2015; 3():33. PubMed ID: 26199729
[TBL] [Abstract][Full Text] [Related]
18. The immunocheckpoints in modern oncology: the next 15 years.
Massari F; Santoni M; Ciccarese C; Santini D
Expert Opin Biol Ther; 2015 Jul; 15(7):917-21. PubMed ID: 26063384
[TBL] [Abstract][Full Text] [Related]
19. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
Villasboas JC; Ansell SM
Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
